Maintaining Investments in New Innovation Act

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Bill 119 HR 1672, also known as the "Genetically Targeted Technologies Access Protection Act," aims to amend title XI of the Social Security Act in order to safeguard access to genetically targeted technologies. The bill seeks to ensure that individuals have continued access to these innovative medical technologies, which are designed to target specific genetic markers in order to provide more personalized and effective treatments.

The proposed legislation recognizes the importance of genetic testing and personalized medicine in improving healthcare outcomes for individuals with genetic conditions or predispositions. By protecting access to genetically targeted technologies, the bill aims to promote advancements in medical research and treatment options for individuals with genetic disorders.

If passed, the bill would provide regulatory oversight and guidance to ensure that genetically targeted technologies are accessible and affordable for those who need them. It would also establish mechanisms to monitor and evaluate the effectiveness of these technologies in improving health outcomes and reducing healthcare costs. Overall, Bill 119 HR 1672 seeks to support the development and utilization of genetically targeted technologies in healthcare, with the goal of improving access to personalized treatments and advancing medical innovation in the United States.